Novocure is a commercial-stage oncology company based in Saint Helier, Jersey. It develops treatments for solid-tumor cancers. Founded in 2000, Novocure is behind a new kind of cancer treatment called Optune, which uses electrical fields to attack brain tumors called glioblastomas.
Is NovoCure stock a buy?
NovoCure Limited - Hold Valuation metrics show that NovoCure Limited may be overvalued. Its Value Score of D indicates it would be a bad pick for value investors. The financial health and growth prospects of NVCR, demonstrate its potential to underperform the market. It currently has a Growth Score of B.
Is NovoCure an Israeli company?
Together with our patients, we strive to extend survival in some of the most aggressive forms of cancer by developing and commercializing our innovative therapy. Learn more about our story, from our founding in Haifa, Israel in 2000 to having grown into a global oncology company today.